Suppr超能文献

对小分子CCR5抑制剂耐药的HIV-1克隆利用CCR5的抑制剂结合形式进行病毒进入。

HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry.

作者信息

Pugach Pavel, Marozsan Andre J, Ketas Thomas J, Landes Elissa L, Moore John P, Kuhmann Shawn E

机构信息

Department of Microbiology and Immunology, Weill Medical College of Cornell University, 1300 York Avenue, Box 62, New York, NY 10021, USA.

出版信息

Virology. 2007 Apr 25;361(1):212-28. doi: 10.1016/j.virol.2006.11.004. Epub 2006 Dec 12.

Abstract

Human immunodeficiency virus type 1 (HIV-1) infection can be inhibited by small molecules that target the CCR5 coreceptor. Here, we describe some properties of clonal viruses resistant to one such inhibitor, SCH-D, using both chimeric, infectious molecular clones and Env-pseudotypes. Studies using combinations of CCR5 ligands, including small molecule inhibitors, monoclonal antibodies (MAbs) and chemokine derivatives such as PSC-RANTES, show that the fully SCH-D-resistant viruses enter target cells by using the SCH-D-bound form of CCR5. However, the way resistance to SCH-D and other small molecule CCR5 inhibitors is manifested depends on the target cell and the nature of the assay (single- vs. multi-cycle). In multi-cycle assays using primary lymphocytes, SCH-D does not inhibit resistant molecular clones, and it can even enhance their infectivity modestly. In contrast, the same viruses (as Env-pseudotypes) are significantly inhibited by SCH-D in single-cycle entry assays using U87-CD4/CCR5 cells, resistance being manifested by incomplete inhibition at high SCH-D concentrations. When a single-cycle, Env-pseudotype entry assay was performed using either U87-CD4/CCR5 cells or PBMC under comparable conditions, entry was inhibited by up to 88% in the former cells but by only 28% in the PBMC. Hence, there are both cell- and assay-dependent influences on how resistance is manifested. We also take this opportunity to correct our previous report that SCH-D-resistant isolates are also substantially cross-resistant to PSC-RANTES [Marozsan, A.J., Kuhmann, S.E., Morgan, T., Herrera, C., Rivera-Troche, E., Xu, S., Baroudy, B.M., Strizki, J., Moore, J.P., 2005. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 338 (1), 182-199]. A substantial element of this resistance was attributable to the unappreciated carry-over of SCH-D from the selection cultures into analytical assays.

摘要

1型人类免疫缺陷病毒(HIV-1)感染可被靶向CCR5共受体的小分子抑制。在此,我们使用嵌合感染性分子克隆和Env假型,描述了对一种此类抑制剂SCH-D耐药的克隆病毒的一些特性。使用包括小分子抑制剂、单克隆抗体(MAb)和趋化因子衍生物(如PSC-RANTES)在内的CCR5配体组合进行的研究表明,完全对SCH-D耐药的病毒通过使用与SCH-D结合形式的CCR5进入靶细胞。然而,对SCH-D和其他小分子CCR5抑制剂耐药性的表现方式取决于靶细胞和检测方法的性质(单循环与多循环)。在使用原代淋巴细胞的多循环检测中,SCH-D不抑制耐药分子克隆,甚至还能适度增强它们的感染性。相比之下,在使用U87-CD4/CCR5细胞的单循环进入检测中,相同的病毒(作为Env假型)被SCH-D显著抑制,在高SCH-D浓度下耐药表现为不完全抑制。当在可比条件下使用U87-CD4/CCR5细胞或PBMC进行单循环Env假型进入检测时,前者细胞中的进入被抑制高达88%,而在PBMC中仅被抑制28%。因此,耐药性的表现存在细胞和检测方法依赖性影响。我们还借此机会纠正我们之前的报告,即对SCH-D耐药的分离株对PSC-RANTES也存在显著的交叉耐药性[Marozsan, A.J., Kuhmann, S.E., Morgan, T., Herrera, C., Rivera-Troche, E., Xu, S., Baroudy, B.M., Strizki, J., Moore, J.P., 2005. 对小分子CCR5抑制剂SCH-417690(SCH-D)耐药的1型人类免疫缺陷病毒分离株的产生及特性。病毒学338 (1), 182 - 199]。这种耐药性的一个重要因素可归因于从选择培养物中未被认识到的SCH-D残留到分析检测中。

相似文献

1
HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry.
Virology. 2007 Apr 25;361(1):212-28. doi: 10.1016/j.virol.2006.11.004. Epub 2006 Dec 12.
7
Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists.
Antimicrob Agents Chemother. 2012 Apr;56(4):1931-5. doi: 10.1128/AAC.06061-11. Epub 2012 Jan 17.
10
Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities.
Virology. 2009 May 10;387(2):296-302. doi: 10.1016/j.virol.2009.02.044. Epub 2009 Mar 20.

引用本文的文献

3
MHC class II proteins mediate sialic acid independent entry of human and avian H2N2 influenza A viruses.
Nat Microbiol. 2024 Oct;9(10):2626-2641. doi: 10.1038/s41564-024-01771-1. Epub 2024 Jul 15.
4
Adaptation of SIVmac to baboon primary cells results in complete absence of baboon infectivity.
Front Cell Infect Microbiol. 2024 Jun 28;14:1408245. doi: 10.3389/fcimb.2024.1408245. eCollection 2024.
7
The chemokine receptor CCR5: multi-faceted hook for HIV-1.
Retrovirology. 2024 Jan 23;21(1):2. doi: 10.1186/s12977-024-00634-1.
8
Development of Zika Virus E Variants for Pseudotyping Retroviral Vectors Targeting Glioblastoma Cells.
Int J Mol Sci. 2023 Sep 23;24(19):14487. doi: 10.3390/ijms241914487.
9
Conformational antigenic heterogeneity as a cause of the persistent fraction in HIV-1 neutralization.
Retrovirology. 2023 May 27;20(1):9. doi: 10.1186/s12977-023-00624-9.
10
Conformational antigenic heterogeneity as a cause of the persistent fraction in HIV-1 neutralization.
Res Sq. 2023 Feb 24:rs.3.rs-2613503. doi: 10.21203/rs.3.rs-2613503/v1.

本文引用的文献

3
Interaction of small molecule inhibitors of HIV-1 entry with CCR5.
Virology. 2006 May 25;349(1):41-54. doi: 10.1016/j.virol.2006.01.018. Epub 2006 Feb 21.
4
CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection.
Antivir Chem Chemother. 2005;16(6):339-54. doi: 10.1177/095632020501600601.
6
Structure of a V3-containing HIV-1 gp120 core.
Science. 2005 Nov 11;310(5750):1025-8. doi: 10.1126/science.1118398.
7
9
V3: HIV's switch-hitter.
AIDS Res Hum Retroviruses. 2005 Feb;21(2):171-89. doi: 10.1089/aid.2005.21.171.
10
Assessing chemokine co-receptor usage in HIV.
Curr Opin Infect Dis. 2005 Feb;18(1):9-15. doi: 10.1097/00001432-200502000-00003.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验